A Swedish life science company with the mission of providing the most sensitive and productive bio-sensing technology for drug development, diagnostics, and quality control.
InSingulo Solution was founded in 2017 after a five-year collaboration between AstraZeneca and Chalmers University exploring the opportunity to overcome today’s challenges of biophysics in drug discovery using single-molecule microscopy. Next to improved sensitivity, extremely low reagent consumption this technology proved extremely valuable for currently challenging targets and being able to work with membrane proteins in their native environment without compromising on data content and quality. While single-molecule techniques are spread in the academic environment the penetration of industrial applications over the last two decades stayed beyond expectations. One of the hurdles of employing single-molecule technologies was always their limited fit for purpose design and lack of robustness.
Our mission is to provide the most sensitive and productive bio-sensing technology for drug development, diagnostics, and quality control. We enable our customers to deliver a high-quality output while securing operational excellence and cost-efficiency.
With our leading technology, humanity will gain access to new and more effective medicines much faster.